The impact of blinding on the results of a randomized, placebo‐controlled multiple sclerosis clinical trial

Type: Article

Publication Date: 1994-01-01

Citations: 333

DOI: https://doi.org/10.1212/wnl.44.1.16

Locations

Similar Works

Action Title Year Authors
+ Issues in the Design and Interpretation of Multiple Sclerosis Clinical Trials 2016 Stephen Krieger
Ilana Katz Sand
Svenja Oynhausen
Aaron Miller
+ Testing for the Integrity of Blinding in Clinical Trials: How Valid Are Forced Choice Paradigms? 2003 Louise Sharpe
Bridget Colette Ryan
Simon Allard
Tom Sensky
+ Meta-analysis of the placebo-treated groups in clinical trials of progressive MS 1996 Brian G. Weinshenker
Maher Issa
Jon C. Baskerville
+ Acceptance of placebo‐control trial design by progressive multiple sclerosis patients 1989 John H. Noseworthy
Margaret K. Vandervoort
George C. Ebers
+ Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis 2024 Cynthia M. C. Lemmens
Suzan van Amerongen
Eva Strijbis
Joep Killestein
+ PDF Chat Blinding in Clinical Trials: Seeing the Big Picture 2021 Thomas F. Monaghan
Christina W. Agudelo
Syed N. Rahman
Alan J. Wein
Jason Lazar
Karel Everaert
Roger R. Dmochowski
+ Assessment of blinding in clinical trials. 2005 Hans‐Heinrich Henneicke‐von Zepelin
+ Aspects of multiple sclerosis that relate to clinical trial design and treatment 1999
+ Blinding in Clinical Trials: A Practical Approach 2012 Heejung Bang
Jongbae J. Park
+ Blinding 2008 Ilana Belitskaya‐Lévy
+ PDF Chat Multiple Sclerosis Clinical Trials: Part 1—Basic Considerations 2001 Robert M. Herndon
+ PDF Chat Clinical trial design for progressive MS trials 2017 Matteo Pardini
Gary Cutter
Maria Pia Sormani
+ Assessment of blinding in clinical trials 2004 Heejung Bang
Liyun Ni
C.E. Davis
+ Common Problems in Designing Therapeutic Trials in Multiple Sclerosis 1983 Jason Weiss
James M. Dambrosia
+ Design and Statistical Issues Related to Testing Experimental Therapy in Multiple Sclerosis 1992 William Weiss
Emanuel M. Stadlan
+ Observational data: Understanding the real MS world 2016 Tomáš Kalinčík
Helmut Butzkueven
+ Statistical Methods for Evaluating Multiple Sclerosis Therapies 1998 John Petkau
+ Masked Monitoring in Clinical Trials — Blind Stupidity? 1998 Curtis L. Meinert
+ Clinical trials in multiple sclerosis 2014 Gary Cutter
Ludwig Kappos
+ Evaluation of Experimental Trials of Therapy in Multiple Sclerosis 1966

Works That Cite This (44)

Action Title Year Authors
+ PDF Chat Developing guidance for a risk-proportionate approach to blinding statisticians within clinical trials: a mixed methods study 2023 Mais Iflaifel
Kirsty Sprange
Jennifer Bell
Andrew Cook
Carrol Gamble
Steven A. Julious
Edmund Juszczak
Louise Linsell
Alan Montgomery
Christopher Partlett
+ PDF Chat Statistical and methodological considerations for reporting RCTs in medical literature 2015 Sangseok Lee
Hyun Kang
+ Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding 2007 Asbjørn Hróbjartsson
Elisabeth Forfang
Mette T. Haahr
Bodil Als‐Nielsen
Stig Brorson
+ Assessment Bias 2005 Peter C Gøtzsche
+ PDF Chat Changes in beliefs identify unblinding in randomized controlled trials: a method to meet CONSORT guidelines 2005 Judy R. Rees
Timothy J. Wade
Deborah A. Levy
John M. Colford
Joan F. Hilton
+ PDF Chat Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition 2016 Brennan C Kahan
Caroline J Doré
Michael Murphy
Vipul Jairath
+ PDF Chat On Minimizing the Risk of Bias in Randomized Controlled Trials in Economics 2016 Alex Eble
Peter Boone
Diana Elbourne
+ Decoupling, Sparsity, Randomization, and Objective Bayesian Inference 2008 Julio Michael Stern
+ Statistics Commentary Series. Commentary No. 44: Internal and External Validity 2020 David L. Streiner
+ A score for measuring the quality of controlled experiments in computing and health informatics 2008 Keith Lui

Works Cited by This (0)

Action Title Year Authors